antifungal agent 2

Antifungal agent 2 is a broad-spectrum inhibitor effective against Cryptococcus, Candida, and Aspergillus species, inhibiting growth at concentrations as low as 0.5 μg mL.

Antifungal agent 6 shows antifungal activity.

Antitumor agent-2 has anti-inflammatory and anti-tumor activity and can be used to study cancer.

Antitrypanosomal agent 2 shows potent and specific antiparasite activities against Trypanosoma brucei.

Antifungal agent 76 has broad-spectrum antifungal activity with a MIC value of 0.25-16 μg/mL.Antifungal agent 76 may act by disrupting fungal cell membranes and can be used to study fungal infections.

Anticonvulsant agent 2 is a potent, orally active anticonvulsant demonstrating antiepileptic activity in a drug-resistant epilepsy model.

Antifungal agent 60 (compound 16), a broad-spectrum ergosterol biosynthesis inhibitor, demonstrates potent activity against seven human pathogenic fungal species, including two fluconazole-resistant C. albicans isolates and two multi-drug resistant Candida auris isolates.

Antifungal Agent 57 (Compound A19) demonstrates potent efficacy against Fluconazole-resistant strains, outperforming Miconazole. It effectively inhibits Candida albicans strains, exhibiting minimum inhibitory concentrations (MIC) ranging from 0.5 to 2 μg/mL [1].

Antifungal agent 25 is an effective, broad-spectrum, metabolically stable antifungal agent in vivo. antifungal agent 25 exhibits antifungal effects against both Candida albicans and fluconazole-resistant Candida albicans.

Antifungal agent 50 exhibits minimum inhibitory concentrations (MICs) ranging from less than 0.063 to 1 μg/mL [1].

Analgesic Agent-2, a selective orally active inhibitor of the NaV1.8 channel, demonstrates an IC50 of 50.18 nM in HEK293 cells that stably express the human NaV1.8 channel, indicating its potential for analgesic activity [1].

Antifungal Agent 61 (Compound 38) is an antifungal agent that inhibits V. mali, with an EC50 value of 0.50 mg/L. This compound impedes V. mali's growth by inducing cell deformation and contraction, diminishing intracellular mitochondrial count, thickening the cell wall, and enhancing cell membrane permeability [1].

Antifungal agent 73 (compound A32) effectively combats azole-resistant candidiasis by disrupting the fungal cell wall and membrane, demonstrating potent in vivo activity against pathogenic fungi, including fluconazole-resistant strains [1].

Compound 9 (Antifungal agent 67), an imidazole class antifungal, exhibits efficacy against Candida and possesses a CC50 value of 33.6 μM in neonatal rat cardiomyoblasts [1].

Antifungal agent 68 (compound 10) effectively combats fungal infections caused by Candida and Cryptococcus gattii through the inhibition of ergosterol biosynthesis, likely via interaction with lanosterol 14α-demethylase (CYP51). The imidazole ring of antifungal agent 68 is proposed to interact with the heme group of CYP51 [1].

Compound 56 (Antidiabetic agent 2) is a glucose-uptake promoter that inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase, with IC50 values of 0.036, 0.042, 0.241, and 0.185 μM, respectively. This agent effectively decreases blood glucose levels [1].

Antifungal Agent 29 (compound 9d) is a potent, selective, and non-toxic agent effective against Cryptococcus neoformans, exhibiting an MIC of ≤0.23 μM [1].

Pradimicin A derivative 26 exhibits antifungal, antiviral, and antiparasitic properties by attaching to d-mannose (Man)-rich glycans in pathogenic organisms [1].

Antifungal agent 51 (5c) exhibits potent antifungal activity against Candida albicans FDC 151, Candida parapsilosis ATCC 22019, and Candida tropicalis FDC 138, with a minimum inhibitory concentration (MIC) value of less than 0.063 μg/mL. It demonstrates low toxicity to cells and no carcinogenicity [1].

Antifungal agent 54 (compound A05) is a potent inhibitor against Fluconazole-resistant strains, outperforming Miconazole in efficacy. It exhibits significant activity against Candida albicans, with minimum inhibitory concentration (MIC) values ranging from 0.25-1 μg mL [1].

Antiplatelet agent 2 is a ticagrelor analogue that exhibits anti-platelet effects and can be used in platelet agglutination studies.

Anti-MRSA agent 2 (compound 14) is a potent inhibitor of methicillin-resistant Staphylococcus aureus (MRSA) (MIC: 0.098 μg ml), exhibiting relatively low toxicity to normal cells. It strongly disrupts bacterial membranes and effectively binds to bacterial genomic DNA.

Antifungal agent 17 showed good antifungal activity against B. cinerea (EC50: 2.86 μg/mL).

Antifungal agent 19 demonstrates potent antifungal activity (EC50 = 0.72 μM).

Antifungal agent 28 (compound 18) is a selective and potent antifungal agent that disrupts mature Candida biofilms and inhibits pathogenic strains of Candida albicans and non-Candida albicans, including fluconazole-resistant strains.

Compound 24f, an antifungal agent also known as 'Antifungal agent 85,' demonstrates potent antibacterial properties, exhibiting minimum inhibitory concentration (MIC) values ranging from 2.5 to 10 μM against diverse Gram-positive bacteria [1].

Antifungal agent 24 (Compound 6) is an antifungal agent that inhibits Candida albicans [MIC: 0.03 μg ml].

Antifungal agent 33 (compound 4e) exhibits potent antifungal activity against Candida albicans with a minimum inhibitory concentration (MIC) of 16 μg ml and an IC50 of 0.19 μg ml.

Antifungal agent 48 (Example 308), active against Cryptococcus neoformans, exhibits a minimum inhibitory concentration (MIC) value of 11 μM [1].

Antifungal agent 78 (compound 25am) shows potent activity against Fusarium graminearum with an EC50 of 13.46 μM [1].

Antifungal agent 72 (Compound B8) demonstrates potent activity by inhibiting the efflux pump function and downregulating resistance-associated genes via disruption of the Pdr1-KIX interaction (K i : 11.7 μM). It exhibits efficacy against Fluconazole-resistant strains, evidenced by a MIC of 63 ng mL, and displays synergistic effects when combined with Fluconazole. This compound is particularly useful for researching C. glabrata infections [1].

Antifungal agent 35 is an effective antifungal agent that potentiates the antifungal activity of fluconazole against C. albicans.

Antifungal agent 20 demonstrates significant antifungal efficacy against a range of fungal pathogens including Colletotrichum gloeosprioides, Rhizoctonia solani, Phytophthora nicotianae var. nicotianae, Diplodia pinea, Colletotrichum acutatum, and Fusarium oxysporum f. sp. niveum.

Antifungal agent 40 inhibits C. alb. CYP51 lanosterol 14α-demethylase (CYP51) by extending into the narrow hydrophobic pocket II, thereby affecting biofilm formation.

Antifungal agent 31 is an orally active, triazole antifungal agent possessing a pyrrolizinone scaffold that exhibits some antifungal activity against Candida and filamentous fungi.Antifungal agent 31 significantly reduced mortality and renal fungal burden in two mouse models of lethal systemic infection.

Apoptotic agent-2 is capable of downregulating Bcl-2 and upregulating Bax and caspase-3 to induce apoptosis, exhibiting anti-proliferative effects that can be used in cancer research.

Antistaphylococcal agent 2 is an anti-staphylococcal therapeutic agent.

Antibacterial Agent 84, an antifungal compound, effectively inhibits candidiasis through a CNB1-dependent mechanism and reduces the viability of the C. albicans biofilm [1].

Antifungal agent 47 (compound 3b) exhibits potent and broad-spectrum fungicidal properties, notably inhibiting respiration and adenosine 5′-triphosphate synthesis, demonstrating its potential as an effective fungicide [1].

Antifungal agent 58 (compound A21) demonstrates high potency against Fluconazole-resistant strains and surpasses Miconazole in effectiveness, inhibiting Candida albicans with minimum inhibitory concentration (MIC) values ranging from 0.06 to 8 μg mL [1].

Antifungal agent 15 exhibits remarkable potency, with EC50 values of 0.52 and 0.50 μg/mL against S. sclerotiorum and B. cinerea, respectively.

Antifungal agent 82 (compound G34) exhibits outstanding in vitro antifungal efficacy against Valsa mali, with an EC50 value of 0.57 μg mL, and demonstrates excellent in vivo protective effects at 40 μg mL [1].

Compound 3a (Antifungal agent 62) exhibits potent fungicidal properties, particularly against Fusarium oxysporum f.sp. cucumerinum, and is utilized in antiviral and fungicidal research [1].

N-(4-Isopropyloxy phenyl)-N-(1H-pyrrol-2-ylmethyl)urea; flavoring agent, flavor modifier is a useful organic compound for research related to life sciences and the catalog number is TNU1282.

Antifungal agent 38 is a heterocyclic disulfide with antifungal and antibacterial properties. It induces hyphal shrinkage, disrupts plasma membrane integrity, and causes cell content damage and leakage [1].

Antifungal agent 49 (Example 112) demonstrates activity against Cryptococcus neoformans with a minimum inhibitory concentration (MIC) of 49 μM [1].

Antihypertensive agent 2 (Compound 4g) effectively antagonizes angiotensin II receptor 1 and reduces blood pressure with potency equal to or greater than Losartan [1].

Compound 5c (Antifungal agent 64) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is applicable for research in antiviral and fungicidal domains [1].

Compound 5d (Antifungal Agent 65) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is utilized in antiviral and fungicidal research [1].